Virtus ETF Advisers LLC Homology Medicines, Inc. Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.39 - $3.12 $49,326 - $110,719	-35,487 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.6 - $4.17 $5,462 - $8,761	-2,101 Reduced 5.59%	35,487 $108,000
Q4 2021 Feb 14, 2022	BUY	$3.64 - $7.78 $32,086 - $68,580	8,815 Added 30.64%	37,588 $137,000
Q3 2021 Nov 15, 2021	SELL	$6.01 - $8.71 $8,990 - $13,030	-1,496 Reduced 4.94%	28,773 $226,000
Q2 2021 Aug 10, 2021	BUY	$6.02 - $9.64 $31,201 - $49,964	5,183 Added 20.66%	30,269 $220,000

Q1 2021 May 17, 2021	BUY	$9.17 - $14.8 $4,034 - $6,512	440 Added 1.79%	25,086 $236,000
Q4 2020 Feb 12, 2021	BUY	$8.92 - $13.29 $34,663 - $51,644	3,886 Added 18.72%	24,646 $278,000
Q3 2020 Nov 13, 2020	SELL	$9.94 - $16.59 $28,020 - $46,767	-2,819 Reduced 11.96%	20,760 $222,000
Q2 2020 Aug 05, 2020	BUY	$12.07 - $19.34 $75,075 - $120,294	6,220 Added 35.83%	23,579 $358,000
Q1 2020 May 14, 2020	SELL	$12.5 - $22.04 $31,762 - $56,003	-2,541 Reduced 12.77%	17,359 $270,000
Q4 2019 Feb 13, 2020	BUY	$11.42 - $22.19 $227,258 - $441,581	19,900 New	19,900 $412,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.